Mirabegron 50mg: Clinical Trials

5 trials of Mirabegron 50mg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 not yet recruiting. 2 Phase 4, 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 42Completed 2
Phase 11Completed 1
Phase 21Completed 1

Follow Mirabegron 50mg: new trials by email Literature Review of Mirabegron 50mg trials Research Report on Mirabegron 50mg

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mirabegron in Patients With Age-Related Macular Degeneration
Mirabegron 50mg, Solifenacin 5mg - Dry AMD, Overactive Bladder
Not yet recruitingUniversity of Naples3122026-04-012026-02-06
A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients
Mirabegron 100 mg, Mirabegron 50mg, mirabegron 25 mg - Cirrhosis, Asthma
Phase 4CompletedKafrelsheikh University782024-07-012026-04-16
Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults
DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg - Healthy
Phase 1CompletedDong-A ST Co., Ltd.372023-08-222024-01-25
Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.
mirabegron 50mg - Overactive Bladder
Phase 4CompletedSamsung Medical Center4342015-06-012018-02-28
Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
Propranolol, Pindolol, Dantrolene - Healthy Volunteers
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)472014-02-072024-10-16

Conditions studied

Urinary Bladder, Overactive (2)  ·  Asthma (1)  ·  Fibrosis (1)

Sponsors

Dong-A ST Co., Ltd. (1)  ·  Kafrelsheikh University (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Samsung Medical Center (1)  ·  University of Naples (1)

Countries

South Korea (2)  ·  Egypt (1)  ·  Italy (1)  ·  United States (1)

Top investigators

Aya Emad Fouda, MSc in Clinical Pharmacy (1)  ·  Kong Y Chen, Ph.D. (1)  ·  Kyu-Sung Lee, Ph.D (1)  ·  Noha Mahmoud ELkhodary, Associate Professor (1)

Results publications

PMID 29980535, PMID 41919172